Device Trial Radar · NCT07853716
REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jun 2029
Study completion Jun 2029
Sponsor
- Lead sponsor
- HeartFlow, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Avania
- First posted
- Oct 2, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
REFINE-CAC is a prospective, multi-center trial assessing the management of asymptomatic participants with CAC scores 1-299 Agatston units or incidental CAC findings on chest computed tomography (CT), all of whom will undergo CCTA and are blinded to the coronary anatomy (e.g., % stenosis). The trial includes a randomized, controlled pathway and a single arm, observational registry pathway.
Conditions
- CAD - Coronary Artery Disease
Interventions
Heartflow AnalysisDevice
REFINE-CAC will provide Heartflow Analyses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who initiate, intensify, cease, or de-escalate lipid lowering therapy (LLT)Time frame: Enrollment to 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
REFINE-CAC Trial Site
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.